The US FDA has extended its approval for AstraZeneca’s acalabrutinib to include initial treatment of mantle cell lymphoma (MCL) in adults who cannot undergo a hematopoietic stem cell transplant. MCL is a rare, aggressive blood cancer and acalabrutinib, sold as Calquence, is the first of its kind approved as front-line therapy for the disease. The drug already had accelerated approval for adults whose MCL had failed at least one prior treatment.
FIN7 Deploys Anubis Backdoor to Hijack Windows Systems via Compromised SharePoint Sites
The Russian cybercrime group FIN7 is linked to a Python-based backdoor named Anubis, providing them remote access to compromised Windows systems, says Swiss cybersecurity firm
